Galzus,
You’ve contributed nothing but noise and sarcasm, and it shows
You claim to be challenging Dstock but you haven’t refuted a single substantive point. You just reacted loudly, emotionally, and without rigor.
1. You scoff at the Merck and NWBO colorectal trial but it is a real collaboration archived in official German research databases. Just because it hasn’t been blasted across press releases doesn’t mean it didn’t exist or wasn’t strategically relevant. The fact that Merck acquired Immune Design for its TLR4 platform not long after should give you pause unless your goal is to ignore context entirely.
2. You pretend that a lack of published results means the trial is meaningless. That is not how oncology works, especially not with early exploratory or immunomodulatory combinations. The absence of publication does not mean the absence of signal. It means it wasn’t time to make it public or that strategic decisions were made about intellectual property, platform acquisition, or redirection.
3. You mock T cell infiltration as though it is fringe, when in fact it is one of the most critical features of tumor response in checkpoint inhibitor synergy. You clearly have not read the FDA guidance on advanced therapy endpoints or reviewed the mechanistic rationale behind combinations like anti PD1 with dendritic cell vaccines, poly ICLC, or TLR agonists. If you had, you would know that DCVax L is not competing with checkpoint inhibitors. It is enabling them.
4. You dismiss pseudoprogression data without understanding its relevance. In glioblastoma, where radiographic response often lags immune activation, a 30 percent pseudoprogression rate is not noise. It is a signal. The correlation with long term survival is well documented, both in peer reviewed literature and in the DCVax Phase 3 results published in JAMA Oncology.
5. Your entire posture is built on mocking terminology, belittling immune mechanisms, and pretending that sarcasm is a substitute for scientific understanding. It is not. The word seminal has an actual definition in biomedical science. So does external control arm. So does immune priming. You just do not use them because you are not here for clarity. You are here to troll.
So here is the bottom line
DStock gave you a path to learn. You chose to posture.
He posted real mechanisms, relevant trial context, and a high level immunological framework.
You came back with snark and no citations.
This is not a debate. This is you getting outclassed and trying to cover it with noise.
Market Data 
Markets 
AI
